Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viking Therapeutics

23.15
-0.5400-2.28%
Volume:4.41M
Turnover:103.61M
Market Cap:2.60B
PE:-15.06
High:24.14
Open:23.61
Low:22.96
Close:23.69
52wk High:81.73
52wk Low:18.92
Shares:112.44M
Float Shares:109.98M
Volume Ratio:0.87
T/O Rate:4.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5368
EPS(LYR):-1.0085
ROE:-19.99%
ROA:-14.99%
PB:3.27
PE(LYR):-22.96

Loading ...

Viking Therapeutics Unveils Positive Results from Phase 2 Trial of VK2735 Tablet for Obesity, Showing Significant Weight Loss

Reuters
·
Aug 19

Viking Therapeutics Inc - Vk2735 Shown to Be Safe and Well-Tolerated in 13-Week Study

THOMSON REUTERS
·
Aug 19

Viking Therapeutics Inc - up to 12.2% Mean Weight Loss With Vk2735 After 13 Weeks

THOMSON REUTERS
·
Aug 19

Viking Therapeutics Announces Positive Top-Line Results From Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity

THOMSON REUTERS
·
Aug 19

Viking Therapeutics Inc - Study Achieves Endpoints With Significant Weight Reduction Using Vk2735

THOMSON REUTERS
·
Aug 19

Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year Bond

Benzinga_recent_news
·
Aug 19

Why a Weight-Loss Pill Is Still a Big Deal -- Heard on the Street -- WSJ

Dow Jones
·
Aug 08

BUZZ-Lilly falls after oral weight-loss drug data fails to impress

Reuters
·
Aug 07

Viking Therapeutics Shares up 6.8% After Rival Eli Lilly Reports Oral Weight-Loss Drug Data

THOMSON REUTERS
·
Aug 07

Viking Therapeutics Shares Gain 8.1% Premarket After Rival Eli Lilly's Late-Stage Data for Oral Weight-Loss Drug

THOMSON REUTERS
·
Aug 07

M&A Is Back. These Stocks Could Be Targets. -- Barrons.com

Dow Jones
·
Aug 02

Stock Track | Viking Therapeutics Soars 5.10% Following Bullish Analyst Ratings and High Price Targets

Stock Track
·
Jul 26

Stock Track | Viking Therapeutics Soars 5.10% Following Bullish Analyst Ratings and High Price Targets

Stock Track
·
Jul 26

BREAKINGVIEWS-GSK revenue hole raises chances of risky M&A move

Reuters
·
Jul 25

BUZZ-Street View: Analysts eye Viking's oral obesity drug data in second half

Reuters
·
Jul 24

Viking Therapeutics Q2 2025 Earnings Call Summary and Q&A Highlights: Advancing Obesity and Diabetes Programs

Earnings Call
·
Jul 24

Viking Therapeutics Shares Fall 7.8% Premarket After Wider Q2 Loss

THOMSON REUTERS
·
Jul 24

Stock Track | Viking Therapeutics Plunges 8.20% Pre-Market Following Q2 Earnings Miss and Wider Losses

Stock Track
·
Jul 24

Stock Track | Viking Therapeutics Plunges 5.36% After Hours as Q2 Earnings Miss Expectations

Stock Track
·
Jul 24

Viking Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Jul 24